|
Alteogen is a biotechnology company that researches, develops, and commercializes biopharmaceuticals, including biosimilars and biobetters. The company operates a platform technology business, licensing its proprietary Hybrozyme technology to convert intravenous infusions into subcutaneous injections, as well as NexP Fusion and NexMab ADC technologies. Key products include ALT-B4 (berahyaluronidase alfa), the standalone hyaluronidase product Tergase (ALT-BB4), and the Eylea biosimilar Eyluxvi (ALT-L9). Alteogen has established license-out agreements with global pharmaceutical partners such as MSD, AstraZeneca, GSK, Daiichi Sankyo, Sandoz, and Novartis. The company also manages a biosimilar portfolio, including a Herceptin biosimilar licensed to Qilu Pharmaceutical and the Eylea biosimilar Eyluxvi, which received European regulatory approval. Alteogen BioLogics serves as a subsidiary for domestic and international sales and marketing operations. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Biotechnology | Homepage alteogen.com |
| Sector Healthcare | IR page alteogen.com | |
|
Tags
biosimilars, biobetters, hyaluronidase, subcutaneous injection, antibody-drug conjugates, fusion proteins, ophthalmology, oncology, growth hormone, protein engineering, Hybrozyme, NexP, NexMab, ALT-B4, berahyaluronidase alfa, Tergase, ALT-BB4, Eyluxvi, ALT-L9, ALT-L2, ALT-P1, ALT-M5, Alteogen BioLogics, Keytruda Qlex
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | — |
| Market cap (USD) | — |
| P/E | — |
| PEG | — |
| P/BV | — |
| P/S | — |
| P/OCF | — |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 39.4% |
| ROI | 31.8% |
| ROIC | 21.4% |
| Profit margin | 65.6% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | — |
| Diluting (TTM) | — |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | 72.7% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 215.859B | 102.855B | 96.523B | 28.806B | 38.746B | 42.426B | 29.229B | 13.703B | 12.104B | 6.844B | 4.727B | 7.043B | 5.527B |
| Net profit | 141.666B | 60.69B | -3.582B | -10.078B | -11.588B | -3.422B | -1.738B | -7.07B | -7.449B | -3.587B | 1.208B | 931.146M | 1.606B |
| Free cash flow | 101.121B | 50.326B | -8.985B | -24.298B | -23.046B | -3.442B | 969.616M | -16.312B | -5.053B | -4.099B | -1.561B | 1.177B | 1.437B |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (KRW) | 1.65B | 1.45B | 4.63B | 1.84B | 2.69B | 4.26B | 8.77B | 16.7B | 20.2B | 29.6B |
| ↳ YoY growth | +304.1% | -12.0% | +218.7% | -60.3% | +46.6% | +58.4% | +105.6% | +90.8% | +20.9% | +46.6% |
| ↳ 5y CAGR | +62.8% | +16.7% | +45.8% | +20.9% | +43.3% | +29.3% | +61.6% | +61.6% | ||
| Borrowings, current (KRW) | 0.00 | 0.00 | 300M | 3.1B | 3.05B | 2.55B | 3.38B | 0.00 | 1.41B | 1.6B |
| Borrowings, non-current (KRW) | 0.00 | 0.00 | 1.5B | 1B | 688M | 938M | 688M | 1.25B | 0.00 | 4.03B |
| Bonds payable (KRW) | — | — | — | — | — | 0.00 | 0.00 | 1.25B | 1.41B | 1.6B |
| Lease liabilities (KRW) | — | — | — | — | — | 275M | 255M | 456M | 345M | 459M |
| Cash and deposits (KRW) | 8.39B | 5.23B | 8.92B | 4.41B | 38.9B | 10.5B | 45.8B | 30.2B | 19B | 66.4B |
| Intangible assets (KRW) | 2.11B | 399M | 508M | 631M | 907M | 11.2B | 47.2B | 89.2B | 112B | 120B |
| Right-of-use assets (KRW) | — | — | — | — | — | 289M | 285M | 488M | 372M | 521M |
| Net debt (borrowings + leases - cash) (KRW) | -8.39B | -5.23B | -7.12B | -313M | -35.2B | -6.78B | -41.5B | -28.5B | -17.2B | -60.3B |
| Cash flow detail | ||||||||||
| Operating cash flow (KRW) | -3.16B | -4.35B | -9.11B | 9.13B | 1.68B | -9.46B | -17.9B | -7.77B | 53B | 124B |
| Purchases of property, plant and equipment (KRW) | -940M | -707M | -7.2B | -8.16B | -5.12B | -13.6B | -6.42B | -1.22B | -2.72B | -23B |
| Purchases of intangible assets (KRW) | -1.61B | -78.5M | -179M | -165M | -375M | -10.5B | -36.1B | -42.2B | -21.7B | -10.4B |
| Share buybacks (cash effect) (KRW) | -811M | -1.18B | 0.00 | 0.00 | — | -794M | -557M | 0.00 | 0.00 | — |
| Interest paid (cash effect) (KRW) | -501,566 | -1.86M | -24.6M | 0.00 | -101M | -26.4M | -102M | -266M | -123M | -141M |
| Income taxes paid (cash effect) (KRW) | -35.1M | -103M | -81M | -191M | -25.9M | -829M | -656M | -148M | -3.16B | -341M |
| Free cash flow (OCF - PPE - intangibles) (KRW) | -5.71B | -5.13B | -16.5B | 804M | -3.82B | -33.5B | -60.4B | -51.2B | 28.6B | 90.7B |
| Income detail | ||||||||||
| Total comprehensive income (KRW) | -3.59B | -7.45B | -7.07B | -1.74B | -3.42B | -11.6B | -10.1B | -3.58B | 60.7B | 145B |
| Comprehensive income to owners (KRW) | -3.59B | -7.45B | -6.87B | -705M | -970M | -6.27B | -8.15B | -3.37B | 62.3B | 142B |
| Reported | Mar 30, 2017 | Mar 30, 2020 | Mar 30, 2020 | Mar 30, 2020 | Aug 10, 2021 | Mar 18, 2024 | Mar 18, 2024 | Mar 18, 2024 | Mar 21, 2025 | Mar 23, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpDisclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Alteogen
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| DFSE | 0.06% | 2,741 | $ 365.48K | Nov 12, 2026 |
| DFAE | 0.04% | 30,619 | $ 4.083M | Nov 12, 2026 |
| DEHP | 0.04% | 1,233 | $ 164.406K | Nov 12, 2026 |
| DFEM | 0.03% | 17,396 | $ 2.32M | Nov 12, 2026 |
| AVEM | 0.02% | 48,373 | $ 6.098M | Nov 16, 2026 |
| DEXC | 0.01% | 281 | $ 37.468K | Nov 12, 2026 |
| AVSE | 0.01% | 213 | $ 26.853K | Nov 16, 2026 |
| AVXC | 0.01% | 403 | $ 50.806K | Nov 16, 2026 |
| DFAX | 0.01% | 5,754 | $ 767.229K | Nov 12, 2026 |
_0f66b.jpg)